NSE · ACUTAAS.NS
Acutaas Chemicals Limited
₹4,003.60+₹26.90 (+0.68%)
Acutaas Chemicals Limited’s quoted price sits in the upper half of its reported 52-week range, 0.71% below the high.
Loading market information…
NSE · AARTIIND.NS · INR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 10:00 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
Aarti Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 21.02% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Aarti Industries Limited’s forward annual dividend is ₹1.00 per share, paid annual. The forward yield is 0.23% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Aarti Industries Limited’s next earnings report is currently expected on Oct 30, 2026, with estimated earnings per share of ₹3.25. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Aarti Industries Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Aarti Industries Limited, established in 1984 and headquartered in Mumbai, India, is a prominent manufacturer and supplier of both specialty chemicals and pharmaceutical products. The company's chemical division produces a wide array of compounds including dichlorobenzene, various nitro-chloro and nitro-benzene derivatives, nitro-toluenes, and sulfur, along with other organic and inorganic substances. These crucial materials serve as intermediates for a diverse range of sectors such as agrochemicals, pharmaceuticals, polymer and fuel additives, fast-moving consumer goods (FMCG), dyes, pigments, paints, printing inks, rubber chemicals, and resins. In the pharmaceutical sphere, Aarti Industries develops active pharmaceutical ingredients (APIs) utilized in medications for conditions like hypertension, asthma, cancer, thalassemia, pain relief, ophthalmic disorders, and central nervous system agents, as well as skincare and decongestant products. They also supply pharmaceutical intermediates and a selection of xanthine derivatives, prominently featuring caffeine anhydrous, theophylline, and related compounds. Beyond its manufacturing capabilities, Aarti Industries provides contract manufacturing and research services. The company maintains a significant global presence, exporting its products to approximately 60 countries across North America, Europe, China, Japan, and other international regions.
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:29 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2025 | May 8, 2025 | ₹2.64+69.23% vs estimate | ₹19.46B+1.87% vs estimate |
|---|
| Q3 2025 | Jan 31, 2025 | ₹1.27-25.73% vs estimate | ₹18.45B+5.41% vs estimate |
|---|
| Q2 2025 | Nov 8, 2024 | ₹1.38-18.82% vs estimate | ₹16.28B+0.82% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₹4,003.60+₹26.90 (+0.68%)
Acutaas Chemicals Limited’s quoted price sits in the upper half of its reported 52-week range, 0.71% below the high.
₹1,616.20+₹35.20 (+2.23%)
Aether Industries Limited’s quoted price sits in the upper half of its reported 52-week range, 10.91% below the high.
₹1,519.40+₹43.00 (+2.91%)
Deepak Nitrite Limited’s quoted price sits in the lower half of its reported 52-week range, 19.94% below the high.
₹5,028.50-₹117.50 (-2.28%)
Atul Ltd’s quoted price sits in the lower half of its reported 52-week range, 29.97% below the high.
₹872.70-₹54.95 (-5.92%)
Aarti Pharmalabs Limited’s quoted price sits in the upper half of its reported 52-week range, 12.94% below the high.
₹177.65-₹7.28 (-3.94%)
IOL Chemicals and Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 20.69% below the high.
₹435.20-₹13.80 (-3.07%)
Aarti Drugs Limited’s quoted price sits in the upper half of its reported 52-week range, 18.5% below the high.
₹1,643.90+₹29.10 (+1.8%)
Tatva Chintan Pharma Chem Limited’s quoted price sits in the upper half of its reported 52-week range, 22.22% below the high.
